May 27
|
Merck Announces Third-Quarter 2025 Dividend
|
May 23
|
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
|
May 23
|
3 Dow Jones Stocks on Our Watchlist
|
May 22
|
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
|
Apr 27
|
Merck & Co., Inc. (MRK): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential
|
Apr 27
|
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Apr 27
|
Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks
|
Apr 26
|
Akeso survival data for ivonescimab misses expectations, STAT says
|
Apr 26
|
Merck First Quarter 2025 Earnings: Beats Expectations
|
Apr 25
|
Company News for Apr 25, 2025
|
Apr 25
|
Q1 2025 Merck & Co Inc Earnings Call
|
Apr 24
|
Stocks to Watch Recap: Alphabet, Intel, P&G, Merck
|
Apr 24
|
Merck Stock Reverses, Though Gardasil 'Woes' Continue In China, Japan
|
Apr 24
|
Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut
|
Apr 24
|
Merck (NYSE:MRK) Faces Patent Lawsuit As Earnings Grow US$317 Million In Q1
|
Apr 24
|
Merck warns of big tariff hit, Hasbro soars, Comcast sinks
|
Apr 24
|
Merck Cuts 2025 Outlook on Tariffs, Charges
|
Apr 24
|
Merck, Nokia, Texas Instruments: Trending Tickers
|
Apr 24
|
Merck takes $200M tariff hit, trimming its gross profits
|
Apr 24
|
Merck’s (NYSE:MRK) Q1 Sales Beat Estimates
|